The genetics of the p53 pathway, apoptosis and cancer therapy

被引：554

作者：

Vazquez, Alexei ^{[1
]}

Bond, Elisabeth E. ^{[3
]}

Levine, Arnold J. ^{[1
,2
]}

Bond, Gareth L. ^{[3
]}

机构：

[1] Inst Adv Study, Princeton, NJ 08540 USA

[2] Canc Inst New Jersey, New Brunswick, NJ 08903 USA

[3] Univ Oxford, Ludwig Inst Canc Res, Oxford OX3 7DQ, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 12期

关键词：

D O I：

10.1038/nrd2656

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The p53 pathway has been shown to mediate cellular stress responses; p53 can initiate DNA repair, cell-cycle arrest, senescence and, importantly, apoptosis. These responses have been implicated in an individual's ability to suppress tumour formation and to respond to many types of cancer therapy. Here we focus on how best to use knowledge of this pathway to tailor current therapies and develop novel ones. Studies of the genetics of p53 pathway components-in particular p53 itself and its negative regulator MDM2-in cancer cells has proven useful in the development of targeted therapies. Furthermore, inherited single nucleotide polymorphisms in p53 pathway genes could serve a similar purpose.

引用

页码：979 / 987

页数：9

共 84 条

[1] A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells [J].

Arva, NC ;

Gopen, TR ;

Talbott, KE ;

Campbell, LE ;

Chicas, A ;

White, DE ;

Bond, GL ;

Levine, AJ ;

Bargonetti, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26776-26787

[2] MDM2 promoter polymorphism and pancreatic cancer risk and prognosis [J].

Asomaning, Kofi ;

Reid, Amy E. ;

Zhou, Wei ;

Heist, Rebecca S. ;

Zhai, Rihong ;

Su, Li ;

Kwak, Eunice L. ;

Blaszkowsky, Lawrence ;

Zhu, Andrew X. ;

Ryan, David P. ;

Christiani, David C. ;

Liu, Geoffrey .

CLINICAL CANCER RESEARCH, 2008, 14 (12) :4010-4015

[3] Haplotype structure and selection of the MDM2 oncogene in humans [J].

Atwal, Gurinder Singh ;

Bond, Gareth L. ;

Metsuyanim, Sally ;

Papa, Moshe ;

Friedman, Eitan ;

Distelman-Menachem, Tal ;

Ben Asher, Edna ;

Lancet, Doron ;

Ross, David A. ;

Sninsky, John ;

White, Tomas J. ;

Levine, Arnold J. ;

Yarden, Ronit .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (11) :4524-4529

[4] IS P53 POLYMORPHISM MAINTAINED BY NATURAL-SELECTION [J].

BECKMAN, G ;

BIRGANDER, R ;

SJALANDER, A ;

SAHA, N ;

HOLMBERG, PA ;

KIVELA, A ;

BECKMAN, L .

HUMAN HEREDITY, 1994, 44 (05) :266-270

[5] p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].

Bergamaschi, D ;

Gasco, M ;

Hiller, L ;

Sullivan, A ;

Syed, N ;

Trigiante, G ;

Yulug, I ;

Merlano, M ;

Numico, G ;

Comino, A ;

Attard, M ;

Reelfs, O ;

Gusterson, B ;

Bell, AK ;

Heath, V ;

Tavassoli, M ;

Farrell, PJ ;

Smith, P ;

Lu, X ;

Crook, T .

CANCER CELL, 2003, 3 (04) :387-402

[6] iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53 [J].

Bergamaschi, Daniele ;

Samuels, Yardena ;

Sullivan, Alexandra ;

Zvelebil, Marketa ;

Breyssens, Hilde ;

Bisso, Andrea ;

Del Sal, Giannino ;

Syed, Nelofer ;

Smith, Paul ;

Gasco, Milena ;

Crook, Tim ;

Lu, Xin .

NATURE GENETICS, 2006, 38 (10) :1133-1141

[7] P53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes [J].

Bonafè, M ;

Salvioli, S ;

Barbi, C ;

Mishto, M ;

Trapassi, C ;

Gemelli, C ;

Storci, G ;

Olivieri, F ;

Monti, D ;

Franceschi, C .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (04) :539-541

[8] MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner [J].

Bond, Gareth L. ;

Hirshfield, Kim M. ;

Kirchhoff, Tomas ;

Alexe, Gabriella ;

Bond, Elisabeth E. ;

Robins, Harlan ;

Bartel, Frank ;

Taubert, Helge ;

Wuerl, Peter ;

Hait, William ;

Toppmeyer, Deborah ;

Offit, Kenneth ;

Levine, Arnold J. .

CANCER RESEARCH, 2006, 66 (10) :5104-5110

[9] MDM2 is a central node in the p53 pathway: 12 years and counting [J].

Bond, GL ;

Hu, WW ;

Levine, AJ .

CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :3-8

[10] A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].

Bond, GL ;

Hu, WW ;

Bond, EE ;

Robins, H ;

Lutzker, SG ;

Arva, NC ;

Bargonetti, J ;

Bartel, F ;

Taubert, H ;

Wuerl, P ;

Onel, K ;

Yip, L ;

Hwang, SJ ;

Strong, LC ;

Lozano, G ;

Levine, AJ .

CELL, 2004, 119 (05) :591-602

← 1 2 3 4 5 6 7 8 9 →